Novel inhibitors of human histone deacetylases: Design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates

Journal of Medicinal Chemistry

Volumn 48, Issue 4, 2005, Pages 1019-1032

  Suzuki, Takayoshi ^a   Nagano, Yuki ^a   Kouketsu, Akiyasu ^a   Matsuura, Azusa ^a   Maruyama, Sakiko ^b   Kurotaki, Mineko ^b   Nakagawa, Hidehiko ^a   Miyata, Naoki ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b Drug Research Department   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2 BROMOACETYLAMINO)HEXANOIC ACID PHENYLAMIDE; 6 (2 DIPROPYNYLAMINO)HEXANOIC ACID PHENYLAMIDE; 6 (3 AMINOUREIDO)HEXANOIC ACID PHENYLAMIDE; 6 (3 HYDROXYUREIDO)HEXANOIC ACID PHENYLAMIDE; 6 METHANESULFONYLAMINOHEXANOIC ACID PHENYLAMIDE; 7 HYDROXYSULFAMOYLHEPTANOIC ACID PHENYLAMIDE; 7 MERCAPTOHEPTANOIC ACID PHENYLAMIDE; 7 METHANESULFONYLHEPTANOIC ACID PHENYLAMIDE; 7 METHYLSULFANYLHEPTANOIC ACID PHENYLAMIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; THIOACETIC ACID S [(6 PHENYLCARBAMOYLPENTYLCARBAMOYL)METHYL] ESTER; THIOISOBUTYRIC ACID S [6 (4 PHENYL 2 THIAZOLYLCARBAMOYL)HEXYL] ESTER; THIOL DERIVATIVE; UNCLASSIFIED DRUG; VORINOSTAT; ZINC;

ARTICLE; CANCER GROWTH; CHEMICAL REACTION KINETICS; DRUG ACETYLATION; DRUG DESIGN; DRUG HYDROLYSIS; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR MODEL; STRUCTURE ANALYSIS; WESTERN BLOTTING;

ACETYLATION; ANTINEOPLASTIC AGENTS; BINDING SITES; BINDING, COMPETITIVE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 13944254995     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049207j     Document Type: Article

References (47)

1. (a) Grozinger, C. M.; Schreiber, S. L. Deacetylase Enzymes: Biological Functions and the Use of Small-Molecule Inhibitors. Chem. Biol. 2002, 9, 3-16.
2. (b) Kouzarides, T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 1999, 9, 40-48.
3. (c) Hassig, C. A.; Schreiber, S. L. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr. Opin. Chem. Biol. 1997, 1, 300-308.
4. Taunton, J.; Hassig, C. A.; Schreiber, S. L. A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p. Science 1996, 272, 408-411.
5. Sambucetti, L. C.; Fischer, D. D.; Zabludoff, S.; Kwon, P. O.; Chamberlin, H. Trogani, N.; Xu, H.; Cohen, D. Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects. J. Biol. Chem. 1999, 274, 34940-34947.
6. (a) Yoshida, M.; Horinouchi, S.; Beppu, T.Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function. BioEssays 1995, 17, 423-430.
7. (b) Richon, V. M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R. A.; Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5705-5708.
8. (c) Richon, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3003-3007.
9. Cohen, L. A.; Amin, S.; Marks, P. A.; Rifkind, R. A.; Desai, D.; Richon, V. M. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res. 1999, 19, 4999-5005.
10. (a) For a review, see: Miller, T. A.; Witter, D. J.; Belvedere, S. Histone Deacetylase Inhibitors. J. Med. Chem. 2003, 46, 5097-5116.
11. (b) For a review, see: Yoshida, M.; Matsuyama, A.; Komatsu, Y.; Nishino, N. From discovery to the coming generation of histone deacetylase inhibitors. Curr. Med. Chem. 2003, 10, 2351-2358.
12. (c) For a review, see: Miller, T. A. Patent status of histone deacetylase inhibitors. Expert Opin. Ther. Pat. 2004, 14, 791-804.
13. Remiszewski, S. W.; Sambucetti, L. C.; Bair, K. W.; Bontempo, J.; Cesarz, D.; Chandramouli, N.; Chen, R.; Cheung, M.; Cornell-Kennon, S.; Dean, K.; Diamantidis, G.; France, D.; Green, M. A.; Howell, K. L.; Kashi, R.; Kwon, P.; Lassota, P.; Martin, M. S.; Mou, Y.; Perez, L. B.; Sharma, S.; Smith, T.; Sorensen, E.; Taplin, F.; Trogani, N.; Versace, R.; Walker, H.; Weltchek-Engler, S.; Wood, A.; Wu, A.; Atadja, P. N-Hydroxy-3-phenyl-2-propenamides as Novel Inhibitors of Human Histone Deacetylase with in Vivo Antitumor Activity: Discovery of (2E)-N-Hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl] amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J. Med. Chem. 2003, 46, 4609-4624.
14. (e) Kim, D.-K. Lee, J. Y.; Kim, J.-S.; Ryu, J.-H.; Choi, J.-Y.; Lee, J. W.; Im, G.-J.; Kim, T.-K.; Seo, J. W.; Park, H.-J.; Yoo, J.; Park, J.-H.; Kim, T.-Y.; Bang, Y.-J. Synthesis and Biological Evaluation of 3-(4-Substituted- phenyl)-N-hydroxy-2-propenamides, a New Class of Histone Deacetylase Inhibitors. J. Med. Chem. 2003, 46, 5745-5751.
15. 2+-Chelating, Motif-Tethered, Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors. J. Med. Chem. 2004, 47, 467-474.
16. 4 Substitutions on Biological Activity. J. Med. Chem. 2004, 47, 1098-1109.
17. (h) Ragno, R.; Mai, A.; Massa, S.; Cerbara, I.; Valente, S.; Bottoni, P.; Scatena, R.; Jesacher, F.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1-methyl-1H-pyrrol- 2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through Structure-Based Drug Design and Docking Studies. J. Med. Chem. 2004, 47, 1351-1359.
18. (i) Glenn, M. P.; Kahnberg, P.; Boyle, G. M.; Hansford, K. A.; Hans, D.; Martyn, A. C.; Parsons, P. G.; Fairlie, D. P. Antiproliferative and Phenotype-Transforming Antitumor Agents Derived from Cysteine. J. Med. Chem. 2004, 47, 2984-2994.
19. (a) Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
20. (b) Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B.-C.; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases. Structure 2004, 12, 1325-1334.
21. (a) Mulder, G. J.; Meerman, J. H. Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: the role of N,O-sulfonation in chemical carcinogenesis of aromatic amines. Environ. Health Perspect. 1983, 49, 27-32.
22. (b) Vassiliou, S.; Mucha, A.; Cuniasse, P.; Georgiadis, D.; Lucet-Levannier, K.; Beau, F.; Kannan, R.; Murphy, G.; Knaeuper, V.; Rio, M. C.; Basset, P.; Yiotakis, A.; Dive, V. Phosphinic Pseudo-Tripeptides as Potent Inhibitors of Matrix Metalloproteinases: A Structure-Activity Study. J. Med. Chem. 1999, 42, 2610-2620.
23. (a) Wong, J. C.; Hong, R.; Schreiber, S. L. Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity. J. Am. Chem. Soc. 2003, 125, 5586-5587.
24. (b) Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Butcher, R. A.; Schreiber, S. L. Multidimensional Chemical Genetic Analysis of Diversity-Oriented Synthesis-Derived Deacetylase Inhibitors Using Cell-Based Assays. Chem. Biol. 2003, 10, 383-396.
25. (a) Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; Mariko, Y.; Yamashita, T.; Nakanishi, O.Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives. J. Med. Chem. 1999, 42, 3001-3003.
26. (b) Vaisburg, A.; Bernstein, N.; Frechette, S.; Allan, M.; Abou-Khalil, E.; Leit, S.; Moradei, O.; Bouchain, G.; Wang, J.; Woo, S. H.; Fournel, M.; Yan, P. T.; Trachy-Bourget, M.-C.; Kalita, A.; Beaulieu, C.; Li, Z.; MacLeod, A. R.; Besterman, J. M.; Delorme, D. (2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 283-287.
27. (a) Frey, R. R.; Wada, C. K.; Garland, R. B.; Curtin, M. L.; Michaelides, M. R.; Li, J.; Pease, L. J.; Glaser, K. B.; Marcotte, P. A.; Bouska, J. J.; Murphy, S. S.; Davidsen, S. K. Trifluoromethyl Ketones as Inhibitors of Histone Deacetylase. Bioorg. Med. Chem. Lett. 2002, 12, 3443-3447.
28. (b) Wada, C. K.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Garland, R. B.; Holms, J. H.; Li, J.; Pease, L. J.; Guo, J.; Glaser, K. B.; Marcotte, P. A.; Richardson, P. L.; Murphy, S. S.; Bouska, J. J.; Tapang, P.; Magoc, T. J.; Albert, D. H.; Davidsen, S. K.; Michaelides, M. R. α-Keto Amides as Inhibitors of Histone Deacetylase. Bioorg. Med. Chem. Lett. 2003, 13, 3331-3335.
29. (c) Vasudevan, A.; Ji, Z.; Frey, R. R.; Wada, C. K.; Steinman, D.; Heyman, H. R.; Guo, Y.; Curtin, M. L.; Guo, J.; Li, J.; Pease, L.; Glaser, K. B.; Marcotte, P. A.; Bouska, J. J.; Davidsen, S. K.; Michaelides, M. R. Heterocyclic Ketones as Inhibitors of Histone Deacetylase. Bioorg. Med. Chem. Lett. 2003, 13, 3909-3913.
30. Wu, T. Y. H.; Hassig, C.; Wu, Y.; Ding, S.; Schultz, P. G. Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. Bioorg. Med. Chem. Lett. 2004, 14, 449-453.
31. (a) Suzuki, T.; Nagano, Y.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. Novel Histone Deacetylase Inhibitors: Design, Synthesis, Enzyme Inhibition, and Binding Mode Study of SAHA-Based Non-hydroxamates. Bioorg. Med. Chem. Lett. 2003, 13, 4321-4326.
32. (b) Suzuki, T.; Kouketsu, A.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 3313-3317.
33. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reaction of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
34. Ondetti, M. A.; Rubin, B.; Cushman, D. W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977, 196, 441-444.
35. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Chem. Rev. 1999, 99, 2735-2776.
36. (a) Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.-H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases. Cancer Res. 2002, 62, 4916-4921.
37. (b) Nishino, N.; Jose, B.; Okamura, S.; Ebisusaki, S.; Kato, T.; Sumida, Y.; Yoshida, M. Cyclic Tetrapeptides Bearing a Sulfhydryl Group Potently Inhibit Histone Deacetylases. Org. Lett. 2003, 5, 5079-5082.
38. Christianson, D. W.; Lipscomb, W. N. Carboxypeptidase A.Acc. Chem. Res. 1989, 22, 62-69.
39. Moree, W. J.; van der Marel, G. A.; Liskamp, R. M. J.Peptides containing a sulfinamide or a sulfonamide moiety: New transition-state analogues. Tetrahedron Lett. 1991, 32, 409-412.
40. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 1993, 268, 22429-22435.
41. Mercaptoacetamide 14 is also attractive for further study. The results will be reported soon.
42. (a) Jung, M.; Brosch, G.; Kölle, D.; Scherf, H.; Gerhäuser, C.; Loidl, P. Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation. J. Med. Chem. 1999, 42, 4669-4679.
43. (b) Remiszewski, S. W.; Sambucetti, L. C.; Atadja, P.; Bair, K. W.; Cornell, W. D.; Green, M. A.; Howell, K. L.; Jung, M.; Kwon, P.; Trogani, N.; Walker, H. Inhibitors of Human Histone Deacetylase: Synthesis and Enzyme and Cellular Activity of Straight Chain Hydroxamates. J. Med. Chem. 2002, 45, 753-757.
44. Gagnard, V.; Leydet, A.; Morere, A.; Montero, J.-L.; Lefebvre, I.; Gosselin, G.; Pannecouque, C.; De Clercq, E.Synthesis and in vitro evaluation of S-acyl-3-thiopropyl prodrugs of Foscarnet. Bioorg. Med. Chem. 2004, 12, 1393-1402.
45. Barber, I.; Rayner, B.; Imbach, J.-L. The prooligonucleotide approach. I. Esterase-mediated reversibility of dithymidine S-alkyl-phosphorothioates to dithymidine phosphorothioates. Bioorg. Med. Chem. Lett. 1995, 5, 563-568.
46. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MACROMODEL - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-467.
47. Mai, A.; Esposito, M.; Sbardella, G.; Massa, S.A new facile and expeditious synthesis of N-hydroxy-N′-phenyloctanediamide, a potent inducer of terminal cytodifferentiation. Org. Prep. Proced. Int. 2001, 33, 391-394.